This systematic review and meta-analysis combined data from 23 studies involving patients with metastatic castration-resistant prostate cancer. The researchers looked at quantitative parameters from PSMA PET imaging, specifically standard uptake value, tumor volume, and total lesion PSMA. They analyzed how these measurements related to overall survival, progression-free survival, and prostate-specific antigen response.
The results showed that higher tumor volume and total lesion PSMA were positively associated with outcomes, while standard uptake value showed a negative association. However, the analysis noted that standard uptake value demonstrated limited predictive value. The study did not report specific safety concerns or adverse events because this was an analysis of imaging data rather than a clinical trial of the drug itself.
Readers should understand that these scan numbers could serve as valuable biomarkers for predicting response to Lu-PSMA therapy. Because the evidence comes from a meta-analysis of existing studies, it provides a broad view of potential prognostic tools. This information helps clarify how imaging might guide treatment decisions for this specific group of patients.